

Screen Testing Cardiovascular Prevention in Asymptomatic Diabetic Patients G. A. Diamond, et al. J Am Coll Cardiol (2007) 49;1915-7  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17498574](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17498574)

Baseline Characteristics of Participants in the Jupiter Trial, a Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy among Individuals with Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein P. M. Ridker, et al. Am J Cardiol (2007) 100;1659-64  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=18036365](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18036365)

(18)Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible: Implications for Atherosclerosis Therapy Trials J. H. Rudd, et al. J Am Coll Cardiol (2007) 50;892-6  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17719477](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17719477)

An Analysis of Mortality Rates with Dual-Antiplatelet Therapy in the Primary Prevention Population of the Charisma Trial T. H. Wang, et al. Eur Heart J (2007) 28;2200-7  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17673448](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17673448)